Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04515615 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

StatusActive, Not Recruiting
PhasePhase 2
SponsorYu jiren
Started2020-09-09
View on ClinicalTrials.gov ↗

Amendment history

2024-09-14
Study Status, Study Design v10
Primary completion dateestimated 2023-09-09→confirmed 2023-12-29
Completion date2025-09→2026-03-29
2023-03-10
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v9
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 4 of 4 sites
2023-01-13
Study Status v8
Primary completion date2022-12-31→2023-09-09
2022-11-05
Study Status v7
Primary completion date2022-09-09→2022-12-31
2022-02-04
Study Status v6
Completion date2026-03→2025-09
Show 5 earlier versions
2022-02-02
Study Status v5
Completion date2024-03→2026-03
2021-11-20
Study Status, Contacts/Locations v4
Primary completion date2021-09→2022-09-09
Study sitesdetails revised at 1 of 4 sites
2021-08-20
Study Status, Contacts/Locations v3
Study sites6→4
2020-09-18
Study Status v2
Start dateestimated 2020-09→confirmed 2020-09-09
2020-09-09
Study Status, Contacts/Locations v1
Start date2020-08→2020-09
Study sitescontacts updated at 1 of 6 sites
2020-08-14
Original filing
Yu jiren
5 trials monitored
See all monitored trials
Gastric Cancer
1,194 trials monitored
See 60 trials at risk
This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the safety of tegafur gimeracil oteracil potassium capsule plus oxaliplatin and Camrelizumab as adjuvant therapy in stage III gastric cancer, including the incidences and types of adverse events. The secondary study objective is to observe and evaluate the disease-free survival (DFS), overall survival (OS) and treatment completion rate.
Trial Details
NCT Number NCT04515615
Lead Sponsor Yu jiren
Conditions Gastric Cancer Stage III
Enrollment 52 participants
Start Date 2020-09-09
Primary Completion 2023-12-29 (estimated)
Study Completion 2026-03-29 (estimated)
Updated on ClinicalTrials.gov 2024-09-19